Home > Insider Trading > Filing (0001694665-23-000160)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1694665	Evelo Biosciences Inc.	EVLO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1180763	Simba Gill	C/O Evelo Biosciences, Inc. One Kendall Square, 600/700, Suite 7-201 Cambridge MA 02139	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-27	15,000	$0.00	18,754	No	4	M	Direct
Common Stock	Disposition	2023-09-28	1,996	$3.94	16,758	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2023-09-27	60,000	$0.00	60,000	$0.00
Common Stock	Restricted Stock Units	Disposition	2023-09-27	15,000	$0.00	15,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
60,000			No	4	A	Direct
45,000			No	4	M	Direct

Footnotes

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person on December 7, 2022, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $3.92 to $3.94, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
The RSUs vested as to 25% of the underlying shares on the grant date of September 27, 2023, with the remaining shares vesting in twelve (12) equal quarterly installments such that all of the RSUs will become vested on the third anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date.